evocatal develops and produces enzymes and fine chemicals, supplying biocatalysts used in the synthesis of pharmaceutical compounds, chemical intermediates and in the manufacture and refinement of consumer goods such as textiles, adhesives, detergents and cosmetics. Led by CEO Dr. Thorsten Eggert, the company is based in Düsseldorf, Germany. In June 2013 evocatal closed a €3.5m Series B funding round. The company intends to use the funds to extend its technology platform and broaden its product portfolio. Investors in the round included existing backers Roland Oetker, High‑Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner, alongside new investors Nrw.Bank and Lanxess. The firm previously raised €2m in growth financing in 2010. evocatal specialises in developing new enzymes and enzyme-based chemical processes, including a portfolio of proprietary biocatalysts (evozymes®). The company has commercialized a fluorescent protein for anaerobic applications used in biotechnological R&D. It also develops novel expression and secretion systems for enzyme production and innovative screening methods. The recent financing is intended to support the development of new products. The company serves the pharmaceutical and fine-chemical sectors with low-molecular-weight compound synthesis expertise. evocatal was founded in 2006 and is based in the Life Science Center of Düsseldorf.

Total raised

$7M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2013